Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
PHASE1CompletedINTERVENTIONAL
Enrollment
108
Participants
Timeline
Start Date
March 31, 2006
Study Completion Date
March 31, 2007
Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL
MnB rLP2086
Trial Locations (3)
4006
Herson
5006
North Adealaide
6840
Perth
All Listed Sponsors
lead
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
NCT00297687 - Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter